Topic: Bristol-Myers Squibb Company

PHILADELPHIA (Reuters) - Relatives of a man whose chemist wife is accused of poisoning him with thallium have filed a wrongful death lawsuit against the pharmaceutical company where she worked and the hospital where he died.Xiaoye Wang, 39, a computer engineer also ...

LONDON/BASEL (Reuters) - Drugmakers AstraZeneca , Novartis , Eli Lilly and Bristol-Myers Squibb issued cautious 2011 forecasts, bracing the sector for challenging patent expiries and price pressures from U.S. health reforms.While AstraZeneca cheered investors with above-forecast fourth-quarter earnings on Thursday and a ...

Bristol-Myers Squibb is a large pharmacuetical company, that specializes in the development of cardiovascular drugs and technology. Bristol-Meyers founded 1858 :

Emtricitabine ( FTC ), with trade name Emtriva (formerly Coviracil ), is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults and children. A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb ...

Bristol-Myers: FDA finds problems at Puerto Rico plant; could delay approval of new drugsU.S. regulators have cited drugmaker Bristol-Myers Squibb Co. for multiple deficiencies at its Puerto Rico manufacturing plant, including glass particles in drug vials and possible contamination of sterile drug ...

Big Pharma isn't completely dead yet. Novo has moved in on Eli Lilly's insulin market in the United States and come up with a longer-acting competitor to Lilly's lizard spit drug Byetta. (An interview with Novo chief Lars Sorensen on Novo's next ...

Exelixis To Receive Initial Payment of $60 Million-. Bristol-Myers Squibb will receive an exclusive worldwide license to develop and commercialize small molecule TGR5 agonists and ROR antagonists. Under the ROR agreement, Bristol-Myers Squibb and Exelixis will collaborate on ROR antagonist programs up ...

So far in 2010, FDA approvals of new small molecule and biological therapies have paced ahead of those in the same period last year, when 27 new treatments, including two vaccines were authorized, according to Fitch Ratings. More late-stage project delays as ...

WITH THE ACQUISITION OF A rival drug maker underway and a slew of new drugs expected to hit the market in the next few years, U.S. pharmaceutical giant Bristol-Myers Squibb (ticker: BMY) is on a roll. At almost $27 a share, the ...

The U.S. Food and Drug Administration has warned drug giant Bristol-Myers Squibb Co. of possible sanctions if it fails to correct "significant violations" of good manufacturing practices at one of its two plants in Puerto Rico.The drugmaker said it has already begun ...